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Methicillin-resistant Staphylococcus aureus (MRSA) was first 
identified in Malaysia in early 1970.1 The MRSA infections rate was 
10 per 1 000 hospital admissions in a local teaching hospital between 
2002 and 2007.2 More than 70% of S. aureus isolates in intensive care 
units (ICUs) in the USA are methicillin-resistant.3 Vancomycin (a 
glycopeptide antibiotic) has been used for nearly 50 years in treating 
MRSA infection. It remains first-line therapy against invasive MRSA 
infections.4 Vancomycin has a narrow therapeutic index and shows a 
time-dependent killing profile.5 Guidelines on recommended dosing 
of vancomycin have been published.4,6
The ratio of the area under the serum drug concentration-versus-
time curve (AUC) and the minimum inhibitory concentration (MIC) 
are among the most useful pharmacokinetic/pharmacodynamic 
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Objectives. The incidence of methicillin-resistant Staphylococcus 
aureus (MRSA) infections in intensive care units in Malaysia is 
significant. Invasive MRSA infections are commonly treated with 
vancomycin. In clinical practice, the serum vancomycin trough 
concentration is used as a surrogate marker of vancomycin efficacy. 
A low concentration of vancomycin may result in less effective 
therapy and increase the risk of bacterial resistance. We evaluated 
the relationship between the resolution of MRSA infections and 
trough concentrations of vancomycin.
Methods. A total of 76 patients admitted between January 2005 
and February 2011 were included in the study. Serum vancomycin 
trough concentration data were collected from the microbiology 
records. The clinical response was evaluated on the basis of clinical 
notes and culture test results.
Results. A total of 262 appropriate trough concentration data was 
included, with a median of 3 trough concentrations per patient. 
Fifty-four patients responded to vancomycin therapy. The initial 
trough concentration did not differ between responders and non-
responders (p=0.135), but the corrected trough concentration was 
higher among responders than among non-responders (11.64±1.50 
mg/l and 9.25±1.59 mg/l, respectively; p=0.036). The average total 
daily dose of vancomycin was significantly higher among the 
responders (p=0.008).
Conclusion. In this critically ill population, a vancomycin 
dose of 15 mg/kg/day was found sufficient to produce optimal 
trough concentrations to eradicate the MRSA infection. This 
study demonstrated the significant relationship between response 
to treatment of MRSA infection and serum vancomycin trough 
concentrations.
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parameters for predicting vancomycin efficacy. However, 
measurement of multiple serum concentrations for AUC calculation 
is not practical in the clinical setting; therefore, the serum trough 
concentration is used as a surrogate marker of AUC and represents 
the most practical method for monitoring the potential efficacy of 
vancomycin. Maximum killing occurs at sustained concentrations 
approximately 4 - 5 times above the MIC.5 In Malaysia, MRSA strains 
with higher MIC at 1 mg/l, 1.5 mg/l and 2 mg/l were found at the rate 
of 41%, 51% and 30%, respectively, in 6 major hospitals.7 Low serum 
concentrations of vancomycin may result in less effective therapy 
and increased risk of bacterial resistance.8 Vancomycin resistance 
may be less likely to develop when serum trough concentrations are 
maintained above 10 mg/l.9
Serum vancomycin trough concentrations of 15 - 20 mg/l have 
been recommended for severe MRSA infections such as bacteraemia, 
endocarditis, osteomyelitis, meningitis and hospital-acquired 
pneumonia.6 However, a trough concentration >15 mg/l has not been 
clearly associated with favourable outcomes.10 An initial response rate 
of 74% was achieved when target trough concentrations of at least 4 
times the MIC were attained.11 Vancomycin trough concentrations 
>15 mg/l were also associated with a higher risk of nephrotoxicity.11
Little information is available regarding the clinical response of 
MRSA infections to serum vancomycin concentrations in critically 
ill patients. We evaluated the relationship between the resolution of 
MRSA infections and the trough concentrations of vancomycin and 
documented the dose regimen of vancomycin received by patients 
in the ICU.
Methods
This retrospective study of critically ill adult patients with MRSA 
infections was conducted in Universiti Kebangsaan Malaysia Medical 
Centre (UKMMC) by using the microbiology records from the 
Infectious Control Unit to identify all appropriate patients admitted 
between January 2005 and February 2011. This study was approved 
by the Research Ethics Committee of Universiti Kebangsaan Malaysia 
(UKM 1.5.3.5/244/NF-001-2011).
Inclusion criteria were: patients age ≥18 years; who had 
microbiologically isolated MRSA; who were treated with vancomycin for 
≥72 hours; who had serum vancomycin trough concentrations monitored 
during therapy; whose baseline white blood cell (WBC) and neutrophil 
counts with ≥2 serial readings were monitored during therapy; and 
whose baseline body temperature with serial body temperature readings 
during therapy were recorded. Patients concurrently treated with other 
antibiotics for MRSA infections (including linezolid, rifampicin, fusidic 
acid and teicoplanin) were excluded.
The medical and laboratory records of eligible patients were 
reviewed. Using a structured data collection form, demographic, 
laboratory, and clinical data were recorded, including: age, sex, body 
weight, diagnosis on admission to ICU, acute physiology and chronic 
health evaluation II (APACHE II) score on ICU admission, date of 
ICU admission, date of discharge from ICU and hospital, co-morbid 
conditions, WBC/neutrophil count, culture and sensitivity, daily 
body temperature, type of ventilation support, use of inotropic 
agents, vancomycin dosing regimen (dose and frequency), serum 
vancomycin trough concentrations achieved, and concurrent non-
MRSA-sensitive antibiotics. The average value was used if there were 
more than one result per day for any laboratory investigation.
Information pertinent to vancomycin therapy was also collected, 
including dose, frequency, timing of doses, timing of missed doses, serum 
vancomycin concentrations, and timing of assay of the concentrations. 
An appropriate serum vancomycin trough concentration was defined 
as the concentration before the next scheduled vancomycin dose 
at steady-state level. All serum vancomycin concentrations were 
measured by fluorescence polarisation immunoassay (COBAS Integra 
800 System, Roche, USA).
The dosage regimen of the patients was classified as ‘stat dose 
basis’ or ‘multiple-dose basis’. Stat dose basis referred to a convenient 
method of dosing for patients with marked renal impairment, 
who are given an initial dose of at least 15 mg/kg, followed by a 
maintenance dose of 250 - 1 000 mg once every few days based on the 
measurement of serum trough concentrations. Multiple-dose basis 
is the traditional method of giving a dose at a fixed frequency, e.g. 
8-hourly, 12-hourly and 24-hourly.12,13
A primary outcome measure was clinical response at the end of 
vancomycin therapy. Clinical responses were evaluated daily after 72 
hours of vancomycin administration. Based on the clinical outcome, 
subjects were divided into ‘response’ and ‘non-response’ groups. 
‘Response’ was defined as improvement of infection-related parameters 
(such as decreasing WBC/neutrophil count, improvement of local signs 
of infections, decreasing body temperature, de-escalation of the use of 
invasive ventilation support to non-invasive ventilation support, and 
discontinuation of inotropic agents, with or without negative culture 
of MRSA at the end of vancomycin treatment). ‘Non-response’ was 
defined as no improvement, or worsening of signs and symptoms of 
infection, with or without persistent positive culture, or a switch from 
vancomycin to an alternative agent based on the clinical judgement of 
clinicians and with or without persistent positive culture.
Initial serum vancomycin trough concentration referred to the 
first steady-state trough concentration. For each patient, a corrected 
average serum vancomycin trough concentration was calculated as 
the trough concentration achieved using the sum of each measured 
trough concentration multiplied by the number of days at that 
level, then divided by the total number of treatment days.11 Clinical 
outcomes for all patients were analysed using the initial vancomycin 
trough concentration achieved and the corrected serum trough 
concentration.
Results
Of 217 patients with MRSA infection and treated with vancomycin, 
only 112 had serum trough concentrations available. Of these 
patients, 76 fulfilled the inclusion and exclusion criteria. Table 1 
shows overall patient demographic data. Male patients comprised 
75%. On admission, the APACHE II score was 18.76±8.18 
(mean±SD). Most isolates were obtained from the respiratory 
tract (46 (60.5%)). There were 17 (22.4%) patients with multiple 
sites of MRSA infection, and 93.4% patients had other concurrent 
infections. All patients with concurrent infections were treated 
with other antibiotics based on culture and sensitivity tests and 
appropriate dose regimen. A total of 262 appropriate trough 
concentration data were included in the study, with a median of 3 
trough concentrations per patient.
Responders to vancomycin therapy (N=54) were categorised into 
2 groups: those who responded clinically with negative culture at 
the end of therapy (n=44), and those who responded clinically but 
without culture result at the end of therapy (n=10). Non-responders 
to therapy (n=22) were classified as: clinically not improved with 
persistent positive culture (n=8), clinically not improved without 
culture result (n=6), changed to alternative agent with persistent 
positive culture (n=7), or changed to alternative agent without culture 
result (n=1).
Table 2 shows patient demographics and serum vancomycin 
trough concentrations for responders and non-responders. All 
aspects of demographic data were similar in the 2 groups. Initial 
trough concentrations did not differ between responders and non-
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responders (p=0.135) but the corrected trough concentrations 
were higher among responders (p=0.036). There was no difference 
between the responders and non-responders distribution as regards 
patients on multiple-dose basis and stat dose basis. The average total 
daily dose was significantly higher in the responders (p=0.008).
Discussion
The initial and corrected vancomycin trough concentrations were 
higher among responders than non-responders, but statistical 
significance was only observed in corrected trough concentrations. 
This could be explained by the time-dependent bacterial killing 
characteristic of vancomycin. The corrected trough concentration 
was estimated by using all measured trough concentrations during 
the entire course of therapy instead of only one measurement 
of initial trough concentration. As such, the corrected trough 
concentration gives a better picture of the vancomycin trough 
concentration throughout the course of therapy. This finding implies 
that serum vancomycin trough concentrations should be monitored 
throughout the course of therapy in critically ill patients. Studies 
have found inter-individual variability in vancomycin disposition 
in critically ill patients owing to factors such as age, renal function 
and underlying illnesses.14,15 Concurrent use of haemodynamically 
active drugs such as inotropes and furosemide have been suggested 
as enhancing vancomycin clearance in this population.14 Therefore, 
close monitoring of trough concentrations is imperative in adjusting 
vancomycin dosage to optimise the treatment effect.
The corrected trough concentration of 11.64±1.50 mg/l among the 
responders compared with 9.25±1.59 mg/l among non-responders 
showed the importance of maintaining vancomycin trough 
concentration above 10 mg/l throughout the course of therapy for 
optimal efficacy. As the maximum killing effect of vancomycin 
depends on sustained concentrations 4 - 5 times above the MIC, it 
is postulated that there is a higher prevalence of MRSA strains with 
higher MIC in the present study location, and may be similar to that 
in other major hospitals in Malaysia.7 Similar findings were reported 
by Zimmermann et al.,16 who found that patients were more likely 
to have WBC counts return to normal and become afebrile within 
72 hours if trough concentrations of vancomycin were 10 mg/l 
or above.16 This finding also supports other reports that trough 
concentration of vancomycin should be maintained above 10 mg/l 
for treatment to be successful and to prevent the development of 
vancomycin resistance.9
The doses of vancomycin given to the critically ill patients were 
determined and adjusted according to the patient’s renal function, 
creatinine clearance and the vancomycin trough concentration 
achieved with the earlier dose. Based on our study findings, a 
vancomycin dose of 15 mg/kg/day would be sufficient to produce 
optimal trough concentrations to eradicate MRSA. This dose 
was estimated to produce the corrected vancomycin trough 
concentration of 11.64±1.50 mg/l, which is between 10 and 15 mg/l 
as previously recommended.9 Others also failed to demonstrate 
the benefits of recently recommended higher serum vancomycin 
trough concentrations >15 mg/l in achieving better clinical 
outcomes.10,11,17 The current findings may justify the vancomycin 
trough concentration between 10 and 15 mg/l as an effective and 
safe target for MRSA infection in critically ill patients. However, 
this observation has not been interpreted in the presence of MICs, 
and caution must be exercised before applying this finding to other 
study populations.
In conclusion, this study demonstrated the significant 
relationship between treatment response of MRSA infection and 
serum vancomycin trough concentrations. In our critically ill adult 
population, a vancomycin dose of 15 mg/kg/day would be sufficient 
to produce an optimal trough concentration of 10 - 15 mg/l that is 
effective against MRSA.
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Table 1. Demographic description of the study subjects
Variables
Value
(N=76)
Age, years (mean±SD) 55.5±16.6
Weight, kg (median (IQR)) 68.4 (56.9 - 80.0)
Gender
Male
Female 
57 (75%)
19 (25%)
ICU admission diagnosis  
Stabilisation pre/post operation
Respiratory failure
Reduced Glasgow coma scale
25 (32.9%)
44 (57.9%)
7 (9.2%) 
Co-morbid conditions
Hypertension
Cerebrovascular accident
Pulmonary disease
Diabetes mellitus
Cardiovascular disease
Renal disease
Liver disease
Trauma
Surgery
Malignancy
Gastro-intestinal disease
Premorbid obesity 
42 (55.3%)
6 (7.9%)
19 (25%) 
27 (35.5%) 
17 (22.4%) 
29 (38.2%) 
15 (19.7%)
19 (25%)
45 (59.2%)
11 (14.5%)
7 (9.2%)
5 (6.6%)
APACHE II score (mean±SD) 18.76±8.18
Infection site
Respiratory 
Blood
Wound
Multiple
46 (60.5%)
5 (6.6%)
8 (10.5%)
17 (22.4%)
Baseline serum creatinine, mmol/l (median 
(IQR)) 72 (47.3 - 128.0)
Baseline CrCl, ml/min (mean±SD) 80.07±9.11
Vancomycin dosing type
Multiple-dose basis
Stat dose basis
58 (76.3)
18 (23.7) 
Concentration readings per patient 
(median (IQR)) 3 (2 - 4)
Vancomycin trough concentrations
Initial, mg/l (mean±SD) 9.69±1.68
Corrected, mg/l (mean±SD) 10.89±1.54
Data are given as number (percentage) unless otherwise indicated.
CrCl = creatinine clearance; IQR = interquartile range; SD = standard deviation.
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Table 2. Patient demographics and serum trough concentrations in responders and non-responders to vancomycin therapy
Variables
Responders
(n=54)
Non-responders
(n=22) p-value
Patient demographics
Age, years (mean±SD) 53.56±16.08 60.41±16.91 0.101
Weight, kg (median (IQR)) 69.9 (59.9 - 82.0) 64.4 (55.1 - 75.8) 0.149
Gender
Male
Female
43 (79.6)
11 (20.4)
14 (63.6)
8 (36.3) 0.144
APACHE II score (mean±SD) 18.89±8.50 18.45±7.51 0.835
Length of stay after initiation of vancomycin (d)
ICU (mean±SD) 10.06±3.47† 20.37±2.42‡ 0.198
Hospital (mean±SD) 33.52±2.57† 49.59±2.00‡ 0.344
Vancomycin trough concentration
Initial, mg/l (mean±SD) 10.26±1.69 8.42±1.64 0.135
Corrected, mg/l (mean±SD) 11.64±1.50 9.25±1.59 0.036*
Vancomycin dosing information
Dosing basis
Multiple-dose
Stat dose
43 (79.6)
11 (20.4)
15 (68.2)
7 (31.8) 0.287
Loading dose given 9 (20.9)§ 1 (6.7)¶ 0.388
Initial total daily dose, mg/kg/day (mean±SD) 18.80±1.70 14.10±1.75 0.039*
Average total daily dose, mg/kg/day (mean±SD) 15.17±1.99 9.42±1.97 0.008*
Cumulative dose received, g (mean±SD) 10.89±2.30 4.71±1.77 <0.001*
Duration of therapy, days (mean±SD) 10.10±1.68 7.62±1.77 0.041*
Data are given as number (percentage) unless otherwise indicated.
*Statistically significantly different.
†
n=29 (total responders who survived).
‡
n=6 (total non-responders who survived).
§
n=43 (total responders who were on multiple-dose basis).
¶
n=15 (total non-responders who were on multiple-dose basis).
